Grape King Bio (TPE:1707) Current Deferred Revenue: NT$0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1707 Grape King Bio Ltd TPE:1707
79 GF Score
Price NT$90.20
GF Value NT$138.92
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Grape King Bio Current Deferred Revenue?

Grape King Bio TPE:1707 +1.12% 79 Current Deferred Revenue is NT$0 Mil as of Mar. 2026. GuruFocus rates TPE:1707 with a GF Score™ of 79/100 and a GF Value™ of NT$138.92 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Grape King Bio's current deferred revenue for the quarter that ended in Mar. 2026 was NT$0 Mil.

Grape King Bio Current Deferred Revenue Related Terms

Grape King Bio Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Grape King Bio's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grape King Bio Current Deferred Revenue Chart

Grape King Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Grape King Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:1707
79GF Score
Grape King Bio Ltd TPE:1707
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$0 Mil mean?
Grape King Bio (TPE:1707) has a Current Deferred Revenue of NT$0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Grape King Bio and its competitors.
Is Grape King Bio's Current Deferred Revenue too high?
Grape King Bio's current Current Deferred Revenue is NT$0 Mil. Overall, Grape King Bio has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Current Deferred Revenue compare to ZTS?
Grape King Bio's Current Deferred Revenue of NT$0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Grape King Bio and its competitors. Grape King Bio's current Current Deferred Revenue is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$138.92, compared to a current price of NT$90.20 — trading 35.1% below its estimated fair value. The current Current Deferred Revenue is NT$0 Mil. Grape King Bio's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Current Deferred Revenue is NT$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grape King Bio (TPE:1707) Overvalued in 2026?

Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued. The current stock price of NT$90.20 is trading 35.1% below its estimated GF Value™ of NT$138.92. GuruFocus considers Grape King Bio to be Significantly Undervalued.

Key valuation signals for TPE:1707:

  • Current Deferred Revenue: NT$0 Mil
  • GF Value™: NT$138.92 vs. price of NT$90.20 (35.1% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grape King Bio Business Description

Address Jinling Road, No. 402, Section 2, Pingzhen District, Pingzhen District, Taoyuan, TWN, 324
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
79GF Score

Get the complete analysis for TPE:1707

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$90.20
Price
NT$138.92
GF Value